Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Standigm logo — The workflow AI drug discovery company

Standigm

The workflow AI drug discovery company

Founded 2015 Korea South Korea South 23 employees Growth Total: $78.57M AI, Biotechnology +3

General Information

Company Name Standigm
Founded Year 2015
Location Korea South Korea South
Founders / Decision Makers
Team member Team member Team member
Employees 23
Industries AI, Biotechnology, Health Care +2
Funding Stage Growth
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Standigm. To contact Standigm, visit standigm.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Standigm compare?

A PDF of Standigm and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Standigm soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Sep 18, 2026

Standigm and Protai have launched a two-year joint R&D program to design selective molecular glue degraders (MGDs).

Get alerts when Standigm shows new signals

AI Insight

Bounce Watch AI
4 weeks ago

Standigm is strategically accelerating its drug discovery and commercialization efforts, evidenced by a new R&D partnership with Protai to develop molecular glue degraders. The company has also gained significant national recognition, being accepted into Korea's Advanced Drug Target Discovery program. Concurrently, Standigm is actively pursuing global pharmaceutical collaborations to commercialize its AI drug discovery platform, STELLA, and its lead compound, MP103, signaling a strong drive for market penetration and pipeline development.

Signal Types
Partnership Recognition Business Development
Strategic Labels
R&D Collaboration Global Expansion Strategic Validation
Next Move: Commercialization
·
Impact: 8/10
·
Ideal For: Growth Equity VCs - AI Drug Discovery

About Standigm

Standigm, founded in 2015, is a Korean-based company specializing in AI-driven drug discovery. With its slogan, "The workflow AI drug discovery company," Standigm leverages cutting-edge proprietary AI platforms to revolutionize the drug development process. It offers a comprehensive solution encompassing novel target identification, lead generation, and drug repurposing, thus streamlining the path to developing commercially viable drug pipelines.

The company takes pride in its innovative early-stage AI-driven workflow, which notably reduces the timeline to generate First-in-Class lead compounds to just seven months. Key platforms like DarkMolFactory™, Standigm ASK™, Standigm BEST™, and Standigm Insight™ automate and optimize various phases of the drug discovery process, potentially saving time and resources.

Standigm last secured a $10.00M growth equity investment from Pavilion Capital on 01 July 2021, highlighting investor confidence in their vision and technological advancements in the fields of AI, Biotechnology, Health Care, Pharmaceutical, and Machine Learning.

Business keywords: AI-driven Drug Discovery, Workflow Automation, Molecular Design, Novel Target Identification, Lead Compound Generation, First-in-Class Drug Development, Target Discovery, Lead Design, Drug Repurposing, Deep Learning, Active Data Parsing, Bot Modeling, Biological Interpretation

Services & Products

AI Drug Discovery
Target Identification
Lead Optimization
AI SaaS & API Solutions
Pipeline Development

Target Customers

Pharmaceutical Companies Biotechnology Firms Research Institutions Healthcare Providers Labs looking for AI solutions

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Growth Equity VC $10.00M 1
Pavilion Capital
Pavilion Capital
01 Jul 2021
Growth Equity VC $44.50M 11
Atinum Investment Kakao Ventures LB Investment
Atinum Investment, Kakao Ventures +9
01 Mar 2021
Series B $8.60M -
01 Nov 2019
Series B $11.50M 6
Atinum Investment Kakao Ventures LB Investment
Atinum Investment, Kakao Ventures +4
01 Mar 2019
Series A $3.00M 3
Atinum Investment Kakao Ventures LB Investment
Atinum Investment, Kakao Ventures +1
01 Aug 2016
Seed $250.00K 1
Kakao Ventures
Kakao Ventures
01 Jan 2016
Seed $440.00K 1
Korea Tech Incubator Program For Startup
01 Oct 2015
Seed $280.00K -
01 May 2015

Standigm Alternatives & Competitors

View All Alternatives
Standigm vs
Insilico Medicine
Insilico Medicine United States

#insilicomeds, #drugdiscovery, #ai, #oncology, #RL, #DL #aging, #longevity #biologics #LLMS #AIDD

IPO
286 employees
AI, Biotechnology
Standigm vs
Variational AI
Variational AI Canada

State-of-the-art generative AI for small molecule drug discovery

Seed
23 employees
AI, Biotechnology
Standigm vs
DeepLife
DeepLife France

AI for digital twin of cells

Series A
31 employees
AI, Biotechnology
Also compare with: Standigm vs Deargen Deargen Standigm vs Genesis Molecular AI Genesis Molecular AI Standigm vs Transition Bio, Inc. Transition Bio, Inc. View all alternatives

FAQ About Standigm

The workflow AI drug discovery company
Standigm was founded in 2015.
Standigm is headquartered in Korea South.
Standigm operates in AI, Biotechnology, Health Care, Pharmaceutical and Machine Learning. Its work centres on AI-driven Drug Discovery, Workflow Automation, Molecular Design and Novel Target Identification. Its customers include Pharmaceutical Companies, Biotechnology Firms and Research Institutions.
Standigm has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Licensing and Performance Based.
Standigm has approximately 23 employees.
Standigm has completed 8 funding rounds, raising a total of $78.57M. The latest funding stage is Growth.
Standigm offers: AI Drug Discovery, Target Identification, Lead Optimization, AI SaaS & API Solutions, Pipeline Development.
Top alternatives and competitors to Standigm include Insilico Medicine, Variational AI, DeepLife, Accutar Biotech, Deargen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Standigm and Insilico Medicine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Standigm, https://bouncewatch.com/company/standigm, updated 21 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes